From a business-model perspective in nuclear, while I would love to have been able to synchronize the slowing of the legacy low energy business with the growth coming from the new category of diagnostic products, we do recognize that Amyvid is the first product in the category of drugs, and because of this, we'll take some time to position and to build. Nevertheless, we believe that PET, and in particular, this new class of drug builds excellent promise for the future. As a reminder, Amyvid is the first of the over 20 diagnostic products, in which we are actively involved in clinical trial.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

These Stocks Pay You to Own Them

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Cramer: Finding the Flaws in Amazon

Cardinal Health: Cramer's Top Takeaways